SCHEMBL26240409

SCHEMBL26240409

CC(C)c1sc(Nc2ncccc2C(=O)O)nc1-c1ccc(Cl)c(Cl)c1

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 4/20 0.52
▸ KMT2A Q03164 4/20 0.52
▸ RAB9A P51151 4/20 0.52
▸ NPC1 O15118 3/20 0.52
▸ SMN1; SMN2 Q16637 2/20 0.52
▸ L3MBTL1 Q9Y468 1/20 0.52
▸ DHODH Q02127 9/20 0.47
▸ CLCN2 P51788 1/20 0.47
▸ LMNA P02545 2/20 0.42
▸ GAA P10253 1/20 0.42
▸ MAPT P10636 1/20 0.42
▸ EIF4E P06730 2/20 0.41
▸ KMO O15229 1/20 0.40
▸ HTT P42858 2/20 0.40
▸ PKM P14618 1/20 0.40
▸ MAPK1 P28482 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.39
▸ NPSR1 Q6W5P4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31454344 0.91 SMN1; SMN2 (0.47) MEN1KMT2ARAB9ANPC1SMN1; SMN2
SCHEMBL23791998 0.89 DHODH (0.46) MEN1KMT2ARAB9ANPC1SMN1; SMN2
SCHEMBL23782383 0.88 SMN1; SMN2 (0.37) MEN1KMT2ARAB9ANPC1SMN1; SMN2
SCHEMBL23782375 0.85 DHODH (0.41) MEN1KMT2ADHODHLMNAEIF4E
SCHEMBL23791728 0.85 MEN1 (0.47) MEN1KMT2ARAB9ANPC1SMN1; SMN2
SCHEMBL30173754 0.85 EIF4E (0.39) MEN1KMT2ARAB9ANPC1SMN1; SMN2
SCHEMBL23782464 0.85 EIF4E (0.39) MEN1KMT2ARAB9ANPC1SMN1; SMN2
SCHEMBL23792003 0.82 DHODH (0.38) DHODHEIF4EKMO
SCHEMBL23782500 0.82 HPGD (0.50) RAB9ANPC1SMN1; SMN2L3MBTL1GAA
SCHEMBL23791999 0.82 FTO (0.41) MEN1KMT2ARAB9ANPC1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230399322-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. 2023-12-14 — — US disclosed
US-20230399322-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. 2023-12-14 — — US disclosed
US-11753403-B2 EIF4E inhibitors and uses thereof PIC Therapeutics, Inc. (US) 2023-09-12 — — US disclosed
US-11753403-B2 EIF4E inhibitors and uses thereof PIC Therapeutics, Inc. (US) 2023-09-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230399322-A1 EIF4E INHIBITORS AND USES THEREOF EIF4E, EIF4EBP1, EIF4A1 MEN1 2104/4885KMT2A 1931/4885RAB9A 1568/4885
US-11753403-B2 EIF4E inhibitors and uses thereof EIF4E, EIF4EBP1, EIF4A1 MEN1 2104/4885KMT2A 1931/4885RAB9A 1568/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback